Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 12Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 5Prostatic Neoplasms 4Solid Tumor 3Neoplasm Metastasis 3Melanoma 3Recurrence 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Choledocholithiasis 2Carcinoma 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Terminal Cancer 1Synovitis, Pigmented Villonodular 1Stomach Neoplasms 1Solid Tumours 1Solid Tumour 1Solid Tumors 1Skin Neoplasms 1Respiratory Aspiration 1Respiration Disorders 1Rectal Neoplasms 1Rare Diseases 1Prostate Cancer Patients 1

Interventions

vorasidenib 1repaglinide 1Rosuvastatin Calcium 1Omeprazole 1Midazolam 1Flurbiprofen 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Healthy Adult Participants × Midazolam × Clear all
NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Servier

Phase 1 Completed
28 enrolled

Healthy Adult Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡